New and experimental HIV treatments: latest news

New and experimental HIV treatments resources

New and experimental HIV treatments features

New and experimental HIV treatments in your own words

New and experimental HIV treatments news from aidsmap

More news

New and experimental HIV treatments news selected from other sources

  • HIV, HCV and TB Pipeline Report

    Drugs, diagnostics, vaccines, preventive technologies, research towards a cure, and immune-based and gene therapies in development.

    21 July 2014 | Treatment Action Group & i-Base
  • Triumeq® (dolutegravir/abacavir/lamivudine) single-tablet regimen receives positive CHMP opinion in Europe for the treatment of HIV

    ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine) for the treatment of HIV infection in adults and adolescents aged 12 years and older and weighing at least 40kg.

    30 June 2014 | Viiv Healthcare press release
  • Dolutegravir in HIV-1 infection: Added benefit in adult patients

    The German Institute for Quality and Efficiency in Health Care (IQWiG) has determined that the new integrase inhibitor drug dolutegravir (Tivicay ®) is of considerable added benefit to treatment-naive patients in comparison with current first-line therapies, and some added benefit to patients who already need to take an integrase inhibitor.

    19 June 2014 | Science Daily
  • Glaxo's ViiV Joins J&J's Janssen to Develop Single-Pill HIV Drug

    Glaxo’s majority-owned ViiV Healthcare venture is collaborating with Johnson & Johnson’s Janssen unit to test a pill combining ViiV’s Tivicay with Janssen’s Edurant, ViiV said today in a statement. Trials are expected to begin next year, the Brentford, U.K.-based company said.

    13 June 2014 | Bloomberg
  • Paper explores new theory on spread of HIV by "popular" cells

    "Popular" cells - could there really be such a thing? According to a new opinion paper published in PLoS Pathogens, the human body may contain cells that have more contact with other cells and could be "superspreaders" of the HIV virus.

    11 June 2014 | HIV / AIDS News From Medical News Today
  • First Patient Enrolled in New Phase 3 Trial Program Investigating a Once-Daily formulation of raltegravir (Isentress)

    Merck (MSD) today announced that the first patient has been enrolled in the company’s global Phase 3 clinical trial, ONCEMRK. ONCEMRK is assessing a once-daily investigational formulation of ISENTRESS® (raltegravir), known as reformulated raltegravir, as part of combination HIV therapy for treatment-naïve HIV-1-infected adults. Raltegravir combines high potency with low toxicity but its more widespread use has been held back by its needing to be taken twice a day.

    06 June 2014 | Merck
  • Dolutegravir in HIV-1 infection: added benefit in adult patients

    German health technology assessment concludes that the dossier compiled by the drug manufacturer provided proof of a considerable added benefit in adults without pretreatment and an indication of a minor added benefit in pretreated adults who require integrase inhibitors (INIs) (i. e. whose treatment should include an INI). These patients have fewer side effects with the new drug than with the respective comparator therapy.

    23 May 2014 | IQWIG
  • Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA

    Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s refiling of two New Drug Applications (NDA) for cobicistat, a pharmacoenhancing or “boosting” agent that increases blood levels of the protease inhibitors atazanavir and darunavir to enable once-daily dosing of these medicines in HIV therapy, and elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults.

    22 April 2014 | Gilead press release
  • Px Wire: Long-Acting Injectables

    In this issue, we review the research on long-acting injectable antiretrovirals for treatment in HIV-positive people and PrEP in HIV-negative people. The pathways for developing these products have key similarities as well as differences—and as the same drugs advance for treatment and PrEP, it will be key to communicate these.

    17 April 2014 | AVAC
  • Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

    If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is developed by Gilead Sciences, Inc.

    15 April 2014 | Bristol-Myers Squibb press release
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.